HotSpot Therapeutics

Biotech · Private

Small molecule drugs that modulate protein allostery and cellular regulation for therapeutic effect

Claim this profile

Follows are private to you and power your alerts

Updated · hotspotthera.com

Sector
Biotech
Federal grants
None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised
None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts
None on recordNo federal contract awards found.
Granted patents
0
40 pending

Capital timeline

No federal awards or Form D filings are on record for this company.

Many early companies raise without filing a Form D, or have not yet won a federal award. New records appear here as the sources update.

Checked: SEC EDGAR Form D through Oct 23, 2026; SBIR and STTR awards through Oct 21, 2026; USAspending contract awards

Founder? Add funding context

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 40
  • PendingIsothiazolylcarboxamide Compounds And Their Use In TherapyUSPTOApplication 19110203
  • PendingCompounds, Compositions And Methods Of Treating DisordersUSPTOApplication 19172091
  • PendingPyrazolylcarboxamide Compounds And Their Use In TherapyUSPTOApplication 19110200
Show all 40 patent records
  • Isothiazolylcarboxamide Compounds And Their Use In TherapyMay 7, 2026 · Application 19110203Pending
  • Compounds, Compositions And Methods Of Treating DisordersApr 23, 2026 · Application 19172091Pending
  • Pyrazolylcarboxamide Compounds And Their Use In TherapyMar 26, 2026 · Application 19110200Pending
  • Heterocyclic Cbl-b Inhibitors For The Treatment Of CancerMar 26, 2026 · Application 19171907Pending
  • Cbl-b Inhibitors And ANTI-PD1/ANTI-PD-L1 For Use In The Treatment Of CancerDec 11, 2025 · Application 19016686Pending
  • Compounds, Compositions And Methods Of Treating DisordersNov 6, 2025 · Application 19172052Pending
  • Cbl-b Inhibitor, Compositions Comprising A Cbl-b Inhibitor In A Method Of Treating A Disease Associated With Cell ProliferationMay 22, 2025 · Application 19016632Pending
  • Treatment Of Cell Proliferation-associated Conditions Using A Combination Of A Clb-b Inhibitor And An Additional Therapeutic AgentMay 15, 2025 · Application 19016716Pending
  • Methods Of Preparation Of Heterocyclic CompoundsMay 8, 2025 · Application 19016575Pending
  • Solid Forms Of A Triazine Derivative As Cbl-b ModulatorMay 8, 2025 · Application 19016543Pending
  • Compounds, Compositions And Methods Of Treating CancerJul 11, 2024 · Application 18286966Pending
  • Pyridinylsulfonamide Compounds And Their Use In TherapyMay 9, 2024 · Application 18237989Pending
  • Pyrazolylsulfonamide Compounds And Their Use In TherapyMay 9, 2024 · Application 18455767Pending
  • Biomarkers Of Cbl-b InhibitionApplication 63662552Pending
  • Indazolyl-piperidine Sulfonamides And Related Compounds And Their Use In TherapyApplication 63605105Pending
  • Compounds, Compositions And Methods Of Treating DisordersApplication PCTUS2023077322Pending
  • Compounds, Compositions And Methods Of Treating DisordersApplication PCTUS2023076248Pending
  • Compounds, Compositions And Methods Of Treating DisordersApplication PCTUS2023076236Pending
  • Pyrazolylcarboxamide Compounds And Their Use In TherapyApplication PCTUS2023073908Pending
  • Isothiazolylcarboxamide Compounds And Their Use In TherapyApplication PCTUS2023073971Pending
  • Pyridinylsulfonamide Compounds And Their Use In TherapyApplication PCTUS2023031115Pending
  • Pyrazolylsulfonamide Compounds And Their Use In TherapyApplication PCTUS2023072880Pending
  • Compounds, Compositions And Methods Of Treatment ThereofApplication PCTUS2023070042Pending
  • Solid Forms And Methods Of UseApplication PCTUS2023070010Pending
  • Methods Of Preparation Of Heterocyclic CompoundsApplication PCTUS2023070059Pending
  • Compounds, Compositions And Methods Of Treatment ThereofApplication PCTUS2023070062Pending
  • Compounds, Compositions And Methods Of Treatment ThereofApplication PCTUS2023070061Pending
  • Compounds, Compositions And Methods Of Treating DisordersApplication 63417366Pending
  • Compounds, Compositions And Methods Of Treating DisordersApplication 63414343Pending
  • Compounds, Compositions And Methods Of Treating DisordersApplication 63414257Pending
  • Isothiazolylcarboxamide Compounds And Their Use In TherapyApplication 63405676Pending
  • Pyrazolylcarboxamide Compounds And Their Use In TherapyApplication 63405668Pending
  • Pyridinylsulfonamide Compounds And Their Use In TherapyApplication 63401491Pending
  • Pyrazolylsulfonamide Compounds And Their Use In TherapyApplication 63401490Pending
  • Solid Forms And Methods Of UseApplication 63388342Pending
  • Compounds, Compositions And Methods Of Treatment ThereofApplication 63388518Pending
  • Compounds, Compositions And Methods Of Treatment ThereofApplication 63388506Pending
  • Compounds, Compositions And Methods Of Treatment ThereofApplication 63388480Pending
  • Methods Of Preparation Of Heterocyclic CompoundsApplication 63388344Pending
  • Compounds, Compositions And Methods Of Treating DisordersApplication PCTUS2022025083Pending

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .